Robert W. Baird Begins Coverage on ARMO Biosciences (ARMO)
Robert W. Baird assumed coverage on shares of ARMO Biosciences (NASDAQ:ARMO) in a report issued on Tuesday, Marketbeat reports. The brokerage set an “outperform” rating and a $67.00 price target on the stock. Robert W. Baird’s price target would suggest a potential upside of 31.94% from the stock’s previous close.
Several other equities research analysts have also recently issued reports on ARMO. BMO Capital Markets began coverage on shares of ARMO Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $75.00 target price on the stock. Jefferies Group began coverage on shares of ARMO Biosciences in a research report on Tuesday. They issued a “buy” rating and a $61.00 target price on the stock.
Shares of ARMO Biosciences (NASDAQ:ARMO) opened at $50.78 on Tuesday. ARMO Biosciences has a 12-month low of $27.00 and a 12-month high of $57.19.
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.